Eton Pharmaceuticals, Inc.
Every calculator, already run for ETON
Open the full toolkit →You have the numbers on ETON. Get the argument.
A written report on which of these readings actually decide the outcome for Eton Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering ETONAnalyst Price Target Disagreement for Eton Pharmaceuticals, Inc.
Wall Street's bull case implies +32% from the current price; the bear case implies +18%. Analysts are relatively aligned on ETON's range.
Ownership & short interest
Insider Trading Activity for ETON
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700…
ETON — frequently asked
Is ETON a buy right now?
Wall Street's consensus rating on Eton Pharmaceuticals, Inc. is Strong Buy across 4 analysts, with a mean price target of $71.00 (+23% vs. the current $57.68). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ETON overvalued?
ETON trades at 147.9x trailing earnings, against a DCF fair value of $5 per share. The current price implies 40% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ETON's next earnings date?
Eton Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 12, 2026. A full ETON research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Eton Pharmaceuticals, Inc.?
Analysts covering Eton Pharmaceuticals, Inc. (ETON) range from a bear-case target of $68.00 to a bull-case high of $76.00, with a mean consensus target of $71.00 across 4 analysts. The spread of $8.00 (14% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Eton Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Eton Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ETON research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Eton Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.